---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-003637"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:54:07.787579+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics Q4 revenue falls 35% to $1.84M, net loss $2.9M; merger completed

## Summary
- Revenue down 35% YoY to $1.84M; prostate brachytherapy sales dropped 50% due to lost largest customer orders.
- Net loss $2.9M ($0.02/share) vs $1.6M ($0.01) last year; operating expenses rose to $3.7M from $2.86M.
- Gross margin plunged to 22.0% from 43.3%, driven by lower prostate sales volume.
- Cash & equivalents $43.8M, no debt; stockholders' equity $55.0M.
- Completed merger with Viewpoint Molecular Targeting on Feb 3; name changed to Perspective Therapeutics; ticker to CATX on Feb 21.

## SEC filing metadata
- accession: 0001437749-23-003637
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/0001437749-23-003637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/isr20230215_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-003637
- JSON: https://secwatch.observer/filing/0001437749-23-003637.json
- Plain text: https://secwatch.observer/filing/0001437749-23-003637.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported the three months ended December 31, 2022 results: revenue $1.84 million.
  - Period: the three months ended December 31, 2022
  - Revenue: $1.84 million
  - Result: reported results
  source text: Revenue for the three months ended December 31, 2022 decreased 35% to $1.84 million versus $2.82 million in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/0001437749-23-003637-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.